Our Story
We are committed to making innovative, life-changing therapies available to patients rapidly and without costly delays, ensuring no promising treatment goes unrealized.
Decades of clinical trial development and oversight experience allow us the opportunity to identify gaps between sponsor needs and available services. The lack of flexibility, overburdened internal staff, and costly service packages of large CROs and clinical vendors create barriers to getting promising therapies to patients. Our objective is to leverage our lessons learned and collaborate with sponsors as extensions of their teams to provide the most, insightful, nimble, and dedicated service possible during the most costly and time-sensitive phase of drug development - clinical trials.
We bridge the gap between innovative science and the clinic with strategic guidance for clinical trials.
OUR TEAM
Bridget O’Keeffe, PhD
President, Co-Founder
Dr. O'Keeffe has held clinical development and medical affairs roles ranging from medical writer to head of clinical development. She has honed multifunctional expertise in the strategy and operations of drug development and maintains attention to both intricate details and the bigger picture. Dr. O'Keeffe is passionate about ensuring team understanding of the research, protocols, and overarching plan to enable quality execution of clinical trials by all participants—sites, sponsor, vendors. She has been acutely involved in drug development at Helix, Exelixis, Genentech, Clovis Oncology, Achaogen, Calithera, Nektar, OncoSec and Ambrx, in addition to contributing to the regulatory approvals of COMETRIQ®/CABOMETYX® (cabozantinib), RUBRACA® (rucaparib), and ZEMDRI ® (plazomicin). Dr. O’Keeffe earned her Doctor of Philosophy in Molecular and Cell Biology at the University of California, Berkeley. She is based in San Francisco, California.
Matthew F. Sieber
Vice President of Operations, Co-Founder
Matt Sieber is a seasoned clinical operations expert and manager. His expertise is the product of nearly 15 years of clinical experience overseeing critical keynote trials, investigator-initiated trials, compassionate use programs, and corporate and client deliverables such as biologics license application (BLA) preparation activities, investigator brochure (IB) updates, and annual safety updates. Prior to founding Anchor Clinical Solutions, Inc., Matt served as Director of Clinical Development for OncoSec Medical Inc., preceded by 12 years in the CRO space managing and directing global clinical trials in Phases I, II, III, and IV across diverse indications including oncology, cardiology, neuroscience, and rare disease. His global experience includes the oversight of operations in over 30 countries on studies ranging in size from 12 to 20,000 subjects. Matt holds a bachelor’s degree from Boston College and certifications in clinical research monitoring and accounting. He is based in Baltimore, Maryland.
CONNECT WITH US